Company profile for Orbital Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. We are building a first-in-kind platform that integrates a critical mass of both established and emerging technologies and delivery mechanisms.With this access to state-of-the-art RNA and novel delivery technologies, Orbital aims to advance an expansive and...
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. We are building a first-in-kind platform that integrates a critical mass of both established and emerging technologies and delivery mechanisms.With this access to state-of-the-art RNA and novel delivery technologies, Orbital aims to advance an expansive and transformational portfolio of RNA therapeutics across a range of human diseases, including in the areas of vaccines, immunomodulation, protein replacement and regenerative medicine.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Cambridge, MA
Telephone
Telephone
+1 (508) 202-7224
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Strengthens-and-Diversifies-Cell-Therapy-Portfolio-with-Acquisition-of-Orbital-Therapeutics/default.aspx

PRESS RELEASE
10 Oct 2025

https://www.businesswire.com/news/home/20250722381311/en/Orbital-Therapeutics-Presents-Non-Human-Primate-Data-for-In-Vivo-CAR-T-Therapy-with-Potential-Best-in-Class-Profile-for-Autoimmune-Disease

BUSINESSWIRE
22 Jul 2025

https://www.businesswire.com/news/home/20250306789950/en

BUSINESSWIRE
06 Mar 2025

https://www.businesswire.com/news/home/20240905242926/en

BUSINESSWIRE
05 Sep 2024

https://www.businesswire.com/news/home/20240903470903/en

BUSINESSWIRE
03 Sep 2024

https://endpts.com/orbital-therapeutics-closes-south-san-francisco-lab-eliminating-some-roles/

ENDPTS
13 Nov 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty